ctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysis
Cell-free circulating tumor DNA (ctDNA) is synthesized by tumor cells, including metastatic tumors, and circulates in the bloodstream. Evidence suggests that ctDNA is a potential predictive and prognostic biomarker for colorectal cancer (CRC), but its predictive efficacy in detecting CRC liver metas...
Main Authors: | Wang Da, Zhao Penglai, Lu Tingting, Ren Jingyao, Zhu Lihui, Han Xiaoyong, Zhang Guangming, Dong Xiaohua, Ma Haizhong, Yu Miao, Cai Hui |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2023-05-01
|
Series: | Open Life Sciences |
Subjects: | |
Online Access: | https://doi.org/10.1515/biol-2022-0615 |
Similar Items
-
Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer
by: Fulong Wang, et al.
Published: (2023-12-01) -
Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
by: Josep Gumà, et al.
Published: (2022-11-01) -
The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal
by: Edina Dizdarevic, et al.
Published: (2022-04-01) -
The Role of ctDNA in Gastric Cancer
by: Justin Mencel, et al.
Published: (2022-10-01) -
Circulating Tumor DNA (ctDNA) Clearance May Predict Treatment Response in Neoadjuvant Colorectal Cancer Management
by: Britney Niemann, et al.
Published: (2024-03-01)